(7R)-7,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (7R)-7,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₁₉H₂₈O₃
• 分子量: 304.4
• InChiKey: RNCGWYKXAJCOLD-BFMBOEQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
  申请人：——

  公开号：US20040121991A1

  公开（公告）日：2004-06-24

  The present invention is related to acute therapeutic uses of dehydroepiandrosterone (DHEA) congeners. These uses include methods for treating or preventing ulcers which comprise administering to a subject either at risk or in need thereof having an ulcer a therapeutic amount of DHEA congener.

  本发明涉及脱氢表雄酮（DHEA）类似物的急性治疗用途。这些用途包括治疗或预防溃疡的方法，包括向患有溃疡风险或需要治疗的受试者施用治疗量的DHEA类似物。
• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。
• Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation
  申请人：Patel Dinesh

  公开号：US20060122160A1

  公开（公告）日：2006-06-08

  The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with a parthenolide to reduce inflammation.

  本发明涉及脱氢表雄酮（DHEA）同系物的治疗用途。更具体地说，本发明涉及将脱氢表雄酮（DHEA）同系物与一种非那雄胺联合施用以减轻炎症。
• Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating depression
  申请人：Patel Dinesh

  公开号：US20060154908A1

  公开（公告）日：2006-07-13

  The present invention is drawn to compositions and methods for treating depression in a subject comprising co-administering therapeutically effective amounts of a DHEA congener and a second antidepressant agent to the subject, wherein the step of co-administrating is more effective in producing an anti-depressive effect compared to the administration of either the DHEA congener or the second antidepressant agent alone at their respective dosages.

  本发明涉及用于治疗受试者抑郁症的组合物和方法，包括向受试者联合施用治疗有效量的 DHEA 同系物和第二种抗抑郁剂，其中联合施用的步骤与以各自的剂量单独施用 DHEA 同系物或第二种抗抑郁剂相比，能更有效地产生抗抑郁效果。
• Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer
  申请人：Patel Dinesh

  公开号：US20060217355A1

  公开（公告）日：2006-09-28

  The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with at least one other pharmaceutically active agent to treat or prevent cancer.

  本发明涉及脱氢表雄酮（DHEA）同系物的治疗用途。更具体地说，本发明涉及将脱氢表雄酮(DHEA)同系物与至少一种其他药物活性剂联合施用，以治疗或预防癌症。